Physician profile
Alex J Vrable
NPI 1710923040
$10,367.45
in general payments reported to CMS, 2019-2025
33 companies · $559 in 2025
The $559 reported for 2025 was more than what 85% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,384 · 2020: $1,489 · 2021: $2,091 · 2022: $1,620 · 2023: $1,655 · 2024: $1,569 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,783.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,782.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,479.89 | 2019-2024 | Tradjenta, Jardiance, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $1,378.86 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $801.44 | 2019-2024 | Xarelto |
| Pfizer INC. | $770.79 | 2019-2025 | |
| Abbvie INC. | $722.57 | 2021-2025 | Ubrelvy, Vraylar |
| Merck Sharp & Dohme LLC | $678.86 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $640.32 | 2019-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $470.00 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $468.10 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $378.51 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $346.01 | 2019-2023 | |
| Mylan Specialty L.P. | $298.23 | 2019-2024 | Yupelri |
| Novo Nordisk INC | $286.58 | 2019-2025 | Ozempic, Rybelsus |
| Arbor Pharmaceuticals, INC. | $247.45 | 2019-2021 | |
| Abbott Laboratories | $223.30 | 2021-2025 | Freestyle Libre 3 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $203.03 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $167.46 | 2019-2024 | Eliquis, Camzyos |
| Astellas Pharma US INC | $111.85 | 2020-2024 | Veozah |
| Amarin Pharma, INC. | $94.95 | 2019-2021 | |
| Exact Sciences Corporation | $94.22 | 2023-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $80.00 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $62.76 | 2021 | |
| Hikma Pharmaceuticals USA | $54.84 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $54.40 | 2024-2025 | Gemtesa |
| Azurity Pharmaceuticals, INC. | $47.69 | 2024 | Edarbi |
| Amgen INC. | $42.96 | 2020 | |
| Harmony Biosciences LLC | $35.00 | 2023-2024 | Wakix |
| Supernus Pharmaceuticals, INC. | $30.77 | 2019 | |
| Nevro Corp. | $28.91 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $20.88 | 2021 | |
| Axsome Therapeutics, INC. | $18.38 | 2023 | Auvelity |
| Lifescan, INC. | $14.24 | 2019 | |
| Sebela Pharmaceuticals INC. | $14.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Vrable listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.